EDX Medical intends to leave the challenger Aquis Stock Exchange and list on the London Stock Exchange’s junior AIM market.

The Cambridge firm creates health testing solutions for medical professionals that improve the rapid detection and characterisation of major diseases, enabling personalised treatment and better outcomes for patients.

It was admitted to trading on the AQSE in June 2021 and was renamed EDX Medical Group Plc following the acquisition by the company of EDX Medical Ltd on 14 November 2022, which constituted a reverse takeover.

Since then the company has raised £15.5m to further develop its business, enter into commercial distribution agreements and expand its laboratory facilities in personnel.

The directors believe that its access to capital from certain funds, its liquidity profile and visibility to investors will be improved by the AIM admission.

The company currently expects to record revenue for the year ended 31st March 2026 of approximately £1.2m.